The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
Official Title: An Open-label Phase 1b Study of ORIC-533 in Patients With Relapsed or Refractory Multiple Myeloma
Study ID: NCT05227144
Brief Summary: The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options
Detailed Description: ORIC-533 is a selective, orally bioavailable, small molecule inhibitor of CD73.This is an open-label, uncontrolled, multicenter, dose-finding study to assess the safety and preliminary antimyeloma activity of ORIC-533 in patients with relapsed or refractory multiple myeloma. After the RP2D has been determined, dose expansion will further evaluate safety and preliminary antimyeloma activity of ORIC-533 in patients with relapsed or refractory multiple myeloma.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
James R. Berenson, MD, Inc., West Hollywood, California, United States
Northside Hospital Cancer Institute, Atlanta, Georgia, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinical Rochester, Rochester, Minnesota, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
The Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health, Charlotte, North Carolina, United States
Swedish Health Services, Seattle, Washington, United States
Princess Margaret Cancer Research Center/University Health Network, Toronto, Ontario, Canada
Name: Pratik S. Multani, MD
Affiliation: ORIC Pharmaceuticals
Role: STUDY_DIRECTOR